Clinical trials: Pemphigus Foliaceus
Pemphigus, Pemphigus Vulgaris
A Safety and Dose-Finding Study of SYNT001 in Subjects With Pemphigus (Vulgaris or Foliaceus)
This was a multicenter, open-label safety study to determine the dose regimen of SYNT001 (ALXN1830) administered intravenously in participants with pemphigus (vulgaris or foliaceus).
- Conditions
- Pemphigus, Pemphigus Vulgaris, Pemphigus Foliaceus
- Trial name
- NCT03075904
- Testing
- ALXN1830
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Pemphigus Foliaceus, Pemphigus Vulgaris
Polyclonal Regulatory T Cells (PolyTregs) for Pemphigus
T cells, a type of white blood cell called a lymphocyte, play an important role in the immune system. One subtype, the regulatory T cell (Treg) helps to regulate the immune system and may provide protection against the…
- Trial name
- NCT03239470
- Testing
- Cohort 1: 1.0 x 10^8 PolyTregs, Cohort 2: 2.5x10^8 PolyTregs
- Where
- 4 sites in United States
- Volunteers
- 5 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Pemphigus Vulgaris, Pemphigus Foliaceus
A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus)
This was a prospective, multicenter, open label extension (OLE) trial on the efficacy, safety, patient outcome measures, tolerability, immunogenicity, PK and PD of efgartigimod PH20 SC in adult PV or PF participants, who…
- Trial name
- ADDRESS+ (NCT04598477)
- Testing
- efgartigimod PH20 SC, prednisone
- Where
- 127 sites in United States, Australia and 19 more
- Volunteers
- 183 people
- Sponsor
- argenx
Pemphigus Vulgaris, Pemphigus Foliaceus
A Study to Evaluate the Safety, PD, PK and Efficacy of ARGX-113 in Patients With Pemphigus
The proposed study is an open-label, non-controlled, adaptive-design Phase II study to evaluate the safety, pharmacodynamics, pharmacokinetics, efficacy, and conditions of use (dosage, frequency of administration at maintenance)…
- Trial name
- NCT03334058
- Testing
- ARGX-113
- Where
- 12 sites in Germany, Hungary and 3 more
- Volunteers
- 34 people
- Sponsor
- argenx
Pemphigus
A Study of PRN1008 in Patients With Pemphigus
This was a Phase 3 randomized, parallel-group, double-blind, placebo-controlled trial (blinded treatment [BT] period) followed by an open-label extension [OLE] period intended to evaluate the efficacy and safety of oral PRN1008…
- Trial name
- NCT03762265
- Testing
- Rilzabrutinib
- Where
- 88 sites in United States, Argentina and 17 more
- Volunteers
- 131 people
- Sponsor
- Principia Biopharma, a Sanofi Company
Pemphigus Vulgaris, Pemphigus Foliaceus
Autoimmune Blistering Diseases Study
Pemphigus and bullous pemphigoid (BP) are severe autoimmune blistering diseases (AIBD) that pose a critical need for new therapeutic approaches.
- Conditions
- Pemphigus Vulgaris, Pemphigus Foliaceus, Bullous Pemphigoid
- Trial name
- AIBD (NCT02753777)
- Testing
- Questionnaires
- Where
- 3 sites in United States
- Volunteers
- 150 people
- Sponsor
- University of Pennsylvania
Type 2 Inflammatory Disorders
Compassionate Use or Expanded Access of Dupilumab
Provide Compassionate Use or Expanded Access of Dupilumab
- Trial name
- NCT04776694
- Testing
- Dupilumab
- Sponsor
- Regeneron Pharmaceuticals
Pemphigus Vulgaris, Pemphigus Foliaceus
A Study to Assess the Efficacy and Safety of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus)
This is a prospective, multicenter, randomized, double-blinded, placebo-controlled trial to investigate the efficacy, safety, patient outcome measures, tolerability, immunogenicity, PK, and PD of efgartigimod PH20 SC in adult…
- Trial name
- ADDRESS (NCT04598451)
- Testing
- efgartigimod PH20 SC, prednisone
- Where
- 134 sites in United States, Australia and 19 more
- Volunteers
- 222 people
- Sponsor
- argenx
Pemphigus Vulgaris, Pemphigus Foliaceus
Phenotypic and Functional Characterisation of Human B-cell Response in Pemphigus
Pemphigus is a rare autoimmune disease involving skin and mucous membranes characterized by the production of pathogenic autoantibodies directed against desmosomal transmembrane glycoproteins belonging to the cadherin…
- Trial name
- CaReLyBP (NCT04117529)
- Testing
- Blood sample
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris